ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 865

Vertebral Fractures In The 3 Year Period Following Steroid Initiation Among Children With Chronic Illnesses

Johannes Roth1, Jinhui Ma1, David A. Cabral2, Peter B. Dent3, Janet E. Ellsworth4, Adam M. Huber5, Kristin M. Houghton2, Roman Jurencak1, Bianca A. Lang5, Maggie Larche3, Claire MA Leblanc6, Brian Lentle2, MaryAnn Matzinger1, Paivi M. Miettunen7, Kiem Oen8, Claire Saint-cyr9, Rosie Scuccimarri10, Nazih Shenouda1, Leanne M. Ward1 and The Canadian STOPP Consortium11, 1University of Ottawa, Ottawa, ON, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3McMaster University, Hamilton, ON, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Dalhousie University, Halifax, NS, Canada, 6McGill University, Montréal, QC, Canada, 7University of Calgary, Calgary, AB, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9Université de Montréal, Montreal, QC, Canada, 10McGill University, Montreal, QC, Canada, 11National Pediatric Bone Health Working Group, Ottawa, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Bone density, fractures, glucocorticoids and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: :  

To describe the pattern and frequency of incident vertebral fractures (VF) in glucocorticoid (GC)-treated children and to determine the clinical factors at baseline that are associated with incident VF.

Methods:

In children with leukemia, rheumatic disorders and nephrotic syndrome, VF were assessed prospectively each year following GC initiation for 3 years, according to the Genant semi-quantitative method. An incident VF was defined as a new fracture in a previously normal vertebral body or worsening of an existing fracture. The 3-year cumulative VF incidence rate was then calculated. Multivariable Poisson regression was used to examine associations between the 3-year total number of incident VF and clinical factors at baseline, including diagnosis, age, gender, pubertal stage, height and body mass index (BMI) Z-scores, calcium and vitamin D intake, physical activity, back pain, and lumbar spine (LS) bone mass density (BMD) Z-score. In addition, prevalent VF (at baseline) as well as cumulative GC exposure and the number of days in receipt of GC until the baseline visit were also assessed for their relationship with 3-year, incident VF.

Results:

404 children were enrolled at a median age of 6.2 years, range 1-17; 50% boys; 188 (46%) had leukemia, 136 (34%) rheumatic conditions, and 80 (20%) nephrotic syndrome. The baseline study visit occurred at a median of 18 days following steroid initiation (inter-quartile range 11-24 days). Forty-four (11%) children had VF at baseline, while 134 incident VF were detected in 55 children over the 3 years.  Overall, 17% of children (95% CI 13-22) had at least one incident VF over the 3 years. The proportions of children with incident VF were as follows: Leukemia: 24% (95% CI 16-32); rheumatic disorders: 13% (95% CI 6-19); nephrotic syndrome 9% (95% CI 1-17). The annual proportion of children with incident VF peaked at 12 months and declined thereafter (p=0.04). Among those with incident VF, 24/55 children (44%) had 1 or more moderate or severe fracture. Most of the VF were new fractures in previously normal vertebral bodies (86%), compared to worsening of existing VF. In Poisson multivariable modeling assessing baseline clinical factors, the following were associated with higher, 3-year VF incident rates: the presence of VF at baseline (incidence Rate Ratio (RR) 6.3, 95% CI 3.2-12.4), female gender (RR 1.8; 95% CI 1.0-3.3), pre-pubertal status (RR 2.1; 95% CI 0.8-5.4), and lower BMD Z-scores (RR 1.4; 95% CI 1.1-1.7). Underlying diagnosis and back pain at baseline were highly correlated with these significant factors (co-linear). Other factors at baseline were not significantly associated with incident VF.

Conclusion:

Within 3 years of steroid initiation, 17% of children had incident VF. VF incidence peaked at 12 months, and almost half of the VF were moderate or severe. Of the factors measured at baseline, prevalent VF were most strongly associated with incident VF over the ensuing 3 years. Female gender, pre-pubertal status and low BMD at baseline were also associated with 3-year incident VF (for every 1 standard deviation reduction in spine BMD Z-score, there was a 40% increased incident VF risk).

Funded by CIHR FRN 64285


Disclosure:

J. Roth,
None;

J. Ma,
None;

D. A. Cabral,
None;

P. B. Dent,
None;

J. E. Ellsworth,
None;

A. M. Huber,
None;

K. M. Houghton,
None;

R. Jurencak,
None;

B. A. Lang,
None;

M. Larche,
None;

C. M. Leblanc,
None;

B. Lentle,
None;

M. Matzinger,
None;

P. M. Miettunen,
None;

K. Oen,
None;

C. Saint-cyr,
None;

R. Scuccimarri,
None;

N. Shenouda,
None;

L. M. Ward,
None;

T. Canadian STOPP Consortium,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vertebral-fractures-in-the-3-year-period-following-steroid-initiation-among-children-with-chronic-illnesses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology